NRx Pharmaceuticals, Inc. (NRXP) received a letter from the FDA Office of Generic Drugs on April 6 2026 that contained only minor formatting comments on the labeling of its preservative‑free ketamine product. The FDA’s feedback indicates no substantive objections, allowing NRx to submit the final label later this month and move closer to a potential approval in summer 2026.
The preservative‑free formulation eliminates benzethonium chloride, a toxic preservative that has been phased out of many topical products. By offering a safer alternative, NRx positions itself to capture a share of the estimated $750 million generic ketamine market and to help address current supply shortages in the U.S. ketamine supply chain.
The FDA letter is a key regulatory milestone that supports NRx’s broader pipeline, which includes a new‑drug application for ketamine to treat severe depression with suicidal ideation and the company’s HOPE Therapeutics clinic network that combines ketamine with other interventional psychiatry modalities. The company also benefits from a Commissioner's National Priority Voucher for a new U.S. manufacturing source of ketamine ingredient, underscoring the strategic importance of ketamine to the federal supply chain.
CEO Jonathan C. Javitt said, "We deeply appreciate the FDA's timely review of the proposed labeling for our generic drug application and look forward to an ongoing collaborative relationship." The comment reflects confidence in the regulatory process and the company’s strategy to bring safer ketamine options to market.
The letter allows NRx to submit the final label later this month, moving the product closer to a commercial launch in Q3 2026. The timing positions the company to capitalize on growing demand for safer ketamine options and strengthens its clinic‑based revenue model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.